Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab - Université Toulouse III - Paul Sabatier - Toulouse INP
Article Dans Une Revue Clinical Microbiology and Infection Année : 2022

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab

Résumé

The SARS-CoV-2 B.1.1.529 (Omicron) variant, divided in five lineages (BA.1/BA.2/BA.3/BA.4/BA.5), harbors numerous spike protein mutations particularly in the receptor-binding domain (RBD). Recent studies showed that the Omicron variant resists the majority of RBD-targeting monoclonal antibodies (mAb). Sotrovimab, a pan-sarbecovirus neutralizing mAb recently authorized, seems to remain efficient to neutralize the omicron variant. However, as it targets a single epitope, the risk of developing resistance mutations is not negligible. We determined the evolution of the virus load, the development of spike mutations, and the evolution of the virus complexity in nasopharyngeal (NP) swabs from sotrovimab-treated ambulatory Omicron-infected patients.

Dates et versions

hal-04009748 , version 1 (01-03-2023)

Identifiants

Citer

Camille Vellas, Pauline Trémeaux, Arnaud del Bello, Justine Latour, Nicolas Jeanne, et al.. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clinical Microbiology and Infection, 2022, 28 (9), pp.1297-1299. ⟨10.1016/j.cmi.2022.05.002⟩. ⟨hal-04009748⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

More